Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points

MeSH terms

• Angiogenesis Inhibitors / administration & dosage*
• Angiogenesis Inhibitors / adverse effects
• Carcinoma, Hepatocellular / blood supply
• Carcinoma, Hepatocellular / diagnostic imaging
• Carcinoma, Hepatocellular / drug therapy*
• Clinical Trials, Phase III as Topic
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Endpoint Determination
• Humans
• Indoles / administration & dosage*
• Indoles / adverse effects
• Liver Neoplasms / blood supply
• Liver Neoplasms / diagnostic imaging
• Liver Neoplasms / drug therapy*
• Pyrroles / administration & dosage*
• Pyrroles / adverse effects
• Sunitinib
• Time Factors
• Tomography, X-Ray Computed
• Treatment Outcome